We have recently read with great interest the article by Sanchez et al entitled “Reduced-
dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism …

We fully agree with Drs. Güner, Kahraman, and Ertürk that full-dose fibrinolytic therapy is a
“double-edged sword” in the treatment of acute pulmonary embolism (PE), 1 mostly due to …

Background The role of fibrinolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. Methods In a randomized, double-blind trial, we compared …

Controversy over the role of fibrinolysis in patients with intermediate-risk pulmonary
embolism (PE) has persisted because of the lack of adequately sized trials. The PEITHO …

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV)
dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic …

Intermediate–high-risk pulmonary embolism (PE) is characterized by right ventricular (RV)
dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic …

To the Editor: In the Pulmonary Embolism Thrombolysis (PEITHO) study (April 10 issue), 1 a
bolus of unfractionated heparin was withheld from 303 patients because they had just …

Why do we not have a precise answer to the question of which patients with pulmonary
embolism (PE), particularly intermediate risk (submassive) PE, ought to receive fibrinolysis …

COVER STORY conclusively demonstrated that it improves mortality (with statistical
significance) more than anticoagulation therapy alone. 1-4 Nevertheless, given the high …

You are the attending physician on duty at the Emergency Department, when John Crow, a
69-year-old Emeritus Professor of cardiology comes with acute dyspnoea [1]. The day before …